Hengrui class 1.1 new drug has been approved with 2 indications and will enter phase 2 clinical practice immediately
-
Last Update: 2018-12-05
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
On December 4, Hengrui Medicine issued a notice on obtaining clinical approval documents, saying that Hengrui medicine and its subsidiary Ruishi biomedical had received the notice of clinical trial of 1.1 chemical medicine shr0302 tablets The approval conclusion shows that: according to the drug administration law of the people's Republic of China and relevant regulations, the shr0302 tablets accepted on August 28, 2018 meet the relevant requirements of drug registration This product is applied for the treatment of moderate and severe ulcerative colitis and the treatment of moderate and severe Crohn's disease, and it is agreed to conduct two phase II clinical trials of rsj10101 and rsj10201 The full text of the announcement is as follows:
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
